192 related articles for article (PubMed ID: 38383423)
21. Prognostic Indicators for H3K27M-Mutant Diffuse Midline Glioma: A Population-Based Retrospective Surveillance, Epidemiology, and End Results Database Analysis.
Adhikari S; Bhutada AS; Ladner L; Cuoco JA; Entwistle JJ; Marvin EA; Rogers CM
World Neurosurg; 2023 Oct; 178():e113-e121. PubMed ID: 37423332
[TBL] [Abstract][Full Text] [Related]
22. H3K27M mutant glioma: Disease definition and biological underpinnings.
Saratsis AM; Knowles T; Petrovic A; Nazarian J
Neuro Oncol; 2024 May; 26(Supplement_2):S92-S100. PubMed ID: 37818718
[TBL] [Abstract][Full Text] [Related]
23. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
[TBL] [Abstract][Full Text] [Related]
24. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq.
Filbin MG; Tirosh I; Hovestadt V; Shaw ML; Escalante LE; Mathewson ND; Neftel C; Frank N; Pelton K; Hebert CM; Haberler C; Yizhak K; Gojo J; Egervari K; Mount C; van Galen P; Bonal DM; Nguyen QD; Beck A; Sinai C; Czech T; Dorfer C; Goumnerova L; Lavarino C; Carcaboso AM; Mora J; Mylvaganam R; Luo CC; Peyrl A; Popović M; Azizi A; Batchelor TT; Frosch MP; Martinez-Lage M; Kieran MW; Bandopadhayay P; Beroukhim R; Fritsch G; Getz G; Rozenblatt-Rosen O; Wucherpfennig KW; Louis DN; Monje M; Slavc I; Ligon KL; Golub TR; Regev A; Bernstein BE; Suvà ML
Science; 2018 Apr; 360(6386):331-335. PubMed ID: 29674595
[TBL] [Abstract][Full Text] [Related]
25. Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?
Manjunath N; Jha P; Singh J; Raheja A; Kaur K; Suri A; Garg A; Sharma MC; Sarkar C; Mohan M; Mani K; Suri V
Neurol Sci; 2021 Mar; 42(3):925-934. PubMed ID: 32666407
[TBL] [Abstract][Full Text] [Related]
26. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Venneti S; Kawakibi AR; Ji S; Waszak SM; Sweha SR; Mota M; Pun M; Deogharkar A; Chung C; Tarapore RS; Ramage S; Chi A; Wen PY; Arrillaga-Romany I; Batchelor TT; Butowski NA; Sumrall A; Shonka N; Harrison RA; de Groot J; Mehta M; Hall MD; Daghistani D; Cloughesy TF; Ellingson BM; Beccaria K; Varlet P; Kim MM; Umemura Y; Garton H; Franson A; Schwartz J; Jain R; Kachman M; Baum H; Burant CF; Mottl SL; Cartaxo RT; John V; Messinger D; Qin T; Peterson E; Sajjakulnukit P; Ravi K; Waugh A; Walling D; Ding Y; Xia Z; Schwendeman A; Hawes D; Yang F; Judkins AR; Wahl D; Lyssiotis CA; de la Nava D; Alonso MM; Eze A; Spitzer J; Schmidt SV; Duchatel RJ; Dun MD; Cain JE; Jiang L; Stopka SA; Baquer G; Regan MS; Filbin MG; Agar NYR; Zhao L; Kumar-Sinha C; Mody R; Chinnaiyan A; Kurokawa R; Pratt D; Yadav VN; Grill J; Kline C; Mueller S; Resnick A; Nazarian J; Allen JE; Odia Y; Gardner SL; Koschmann C
Cancer Discov; 2023 Nov; 13(11):2370-2393. PubMed ID: 37584601
[TBL] [Abstract][Full Text] [Related]
27. [Clinical Findings of Thalamic and Brainstem Glioma Including Diffuse Midline Glioma, H3K27M Mutant:A Clinical Study].
Kim Y; Kudo T; Tamura K; Sumita K; Kobayashi D; Tanaka Y; Inaji M; Nariai T; Ishii K; Maehara T
No Shinkei Geka; 2021 Jul; 49(4):901-908. PubMed ID: 34376622
[TBL] [Abstract][Full Text] [Related]
28. Significance of H3K27M mutation with specific histomorphological features and associated molecular alterations in pediatric high-grade glial tumors.
Bozkurt SU; Dagcinar A; Tanrikulu B; Comunoglu N; Meydan BC; Ozek M; Oz B
Childs Nerv Syst; 2018 Jan; 34(1):107-116. PubMed ID: 29063957
[TBL] [Abstract][Full Text] [Related]
29. H3K27M-Altered Diffuse Midline Gliomas Among Adult Patients: A Systematic Review of Clinical Features and Survival Analysis.
Bin-Alamer O; Jimenez AE; Azad TD; Bettegowda C; Mukherjee D
World Neurosurg; 2022 Sep; 165():e251-e264. PubMed ID: 35697228
[TBL] [Abstract][Full Text] [Related]
30. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
[No Abstract] [Full Text] [Related]
31. Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma.
Wierzbicki K; Ravi K; Franson A; Bruzek A; Cantor E; Harris M; Homan MJ; Marini BL; Kawakibi AR; Ravindran R; Teodoro R; Yadav VN; Koschmann C
Curr Oncol Rep; 2020 Feb; 22(2):19. PubMed ID: 32030483
[TBL] [Abstract][Full Text] [Related]
32. H3K27M-mutant diffuse midline glioma with extensive intratumoral microthrombi in a young adult with COVID-19-associated coagulopathy.
Pun M; Haggerty-Skeans J; Pratt D; Fudym Y; Al-Holou WN; Camelo-Piragua S; Venneti S
Acta Neuropathol; 2020 Aug; 140(2):227-229. PubMed ID: 32601911
[No Abstract] [Full Text] [Related]
33. Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma.
Cantor E; Wierzbicki K; Tarapore RS; Ravi K; Thomas C; Cartaxo R; Nand Yadav V; Ravindran R; Bruzek AK; Wadden J; John V; May Babila C; Cummings JR; Rahman Kawakibi A; Ji S; Ramos J; Paul A; Walling D; Leonard M; Robertson P; Franson A; Mody R; Garton HJL; Venneti S; Odia Y; Kline C; Vitanza NA; Khatua S; Mueller S; Allen JE; Gardner SL; Koschmann C
Neuro Oncol; 2022 Aug; 24(8):1366-1374. PubMed ID: 35137228
[TBL] [Abstract][Full Text] [Related]
34. Clinicohistoradiological and surgical outcome in diffuse midline glioma.
Kumar Suman A; Bhattacharjee S; Uppin MS; Fathima ST
Childs Nerv Syst; 2024 Jan; 40(1):65-71. PubMed ID: 37644138
[TBL] [Abstract][Full Text] [Related]
35. Case series of diffuse extraneural metastasis in H3F3A mutant high-grade gliomas: Clinical, molecular phenotype and literature review.
Mohiuddin S; Maraka S; Usman Baig M; Gupta S; Muzzafar T; Valyi-Nagy T; Lindsay H; Moody K; Razvi S; Paulino A; Slavin K; Gondi V; McCutcheon I; Zaky W; Khatua S
J Clin Neurosci; 2021 Jul; 89():405-411. PubMed ID: 34053821
[TBL] [Abstract][Full Text] [Related]
36. Diffuse midline glioma H3K27M mutation in adult: A case report.
Bhattarai AM; Mainali G; Jha P; Karki P; Adhikari A; Pandit A; Bhattarai AM
Ann Med Surg (Lond); 2022 Apr; 76():103567. PubMed ID: 35495373
[TBL] [Abstract][Full Text] [Related]
37. Spinal intramedullary H3K27M mutant glioma with vertebral metastasis: a case report.
Handis C; Tanrıkulu B; Danyeli AE; Özek MM
Childs Nerv Syst; 2021 Dec; 37(12):3933-3937. PubMed ID: 33742289
[TBL] [Abstract][Full Text] [Related]
38. Demonstrated efficacy and mechanisms of sensitivity of ONC201: H3K27M-mutant diffuse midline glioma in the spotlight.
Arrillaga-Romany I; Miller JJ
Neuro Oncol; 2024 Jun; 26(6):991-992. PubMed ID: 38588460
[No Abstract] [Full Text] [Related]
39. Advanced MR imaging and
Piccardo A; Tortora D; Mascelli S; Severino M; Piatelli G; Consales A; Pescetto M; Biassoni V; Schiavello E; Massollo M; Verrico A; Milanaccio C; Garrè ML; Rossi A; Morana G
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1685-1694. PubMed ID: 31030232
[TBL] [Abstract][Full Text] [Related]
40. A novel mouse model of diffuse midline glioma initiated in neonatal oligodendrocyte progenitor cells highlights cell-of-origin dependent effects of H3K27M.
Tomita Y; Shimazu Y; Somasundaram A; Tanaka Y; Takata N; Ishi Y; Gadd S; Hashizume R; Angione A; Pinero G; Hambardzumyan D; Brat DJ; Hoeman CM; Becher OJ
Glia; 2022 Sep; 70(9):1681-1698. PubMed ID: 35524725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]